ArticleJAAD international2025

Adverse events associated with bimekizumab for moderate-to-severe plaque psoriasis: A retrospective, multicenter, post-hoc analysis.

Nikki Zangenah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.